Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
September 2020
-
In The News
Proactive scenario planning and supply risk management
Steffen Lang, Global Head Novartis Technical Operations, on communication, data and automation during the COVID-19 crisis. -
Media Release
Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)
Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1 Subgroup analyses of the EXPAND trial showed the… -
Media Release
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates and MRI lesion activity and demonstrated… -
Not your grandparents’ nuclear medicine
Novartis is taming nuclear power and putting it to use to treat advanced cancer.
-
Featured News
New report shows how AI in health is critical for COVID-19 response and recovery
AI offers the greatest potential to transform health systems from being reactive to proactive, predictive, and even preventive.
-
Media Release
Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum
Novartis will present 48 abstracts from its leading MS portfolio, including new data on recently FDA-approved Kesimpta® (ofatumumab)—the first and only self-administered, targeted B-cell therapy for… -
Reimagining asthma care: how data and digital could bring asthma management goals within reach
Bertrand Bodson explains the Novartis strategy for digital innovation in asthma care.
-
Media Release
Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks1 Once-daily Enerzair… -
Media Release
Novartis announces NEJM publication of pivotal study of Tabrecta™ in patients with METex14 metastatic non-small cell lung cancer
Tabrecta™ (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon… -
Statement
AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy
-
Featured News
Bold Advocates for Blood Cancers and Blood Disorders
Blood diseases place a huge burden on individual patients, their families and on wider society. Yet advances in hematology treatment give so much cause for hope. It’s our responsibility to turn that hope into reality. Hear from five bold advocates who inspire us.
-
Media Release
New collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines
The collaboration aims to help alleviate supply and logistical constraints in the African Union member states Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division…
Pagination
- ‹ Previous page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- …
- 154
- › Next page
Test disclaimer...!!!